Coagulopathy and COVID‑19

Yazıcı, Onur; Bozkuş, Fulsen; Demirci, Nilgün; Gülhan, Pınar Yıldız; Coşkun, Funda

doi:10.4103/ejop.ejop_49_20

Onur Yazıcı¹ ,

Fulsen Bozkuş² ,

Nilgün Demirci³ ,

Pınar Yıldız Gülhan⁴ ,

Funda Coşkun⁵

¹Department of Pulmonary Diseases, University of Adnan Menderes School of Medicine, Aydİn, Turkey
²Department of Pulmonary Diseases, University of Kahramanmaras Sutcu Imam School of Medicine, Kahramanmaras, Turkey
³Department of Pulmonary Diseases, University of Gazi School of Medicine, Ankara, Turkey
⁴Department of Pulmonary Diseases, University of Duzce School of Medicine, Düzce, Turkey
⁵Department of Pulmonary Diseases, University of Bursa Uludag School of Medicine, Bursa, Turkey

Eurasian Journal of Pulmonology 2020; 22(): 67-69 DOI: 10.4103/ejop.ejop_49_20

Full Text PDF

Abstract

Caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19) is a potentially fatal disease as a global public health issue. Several mechanisms may be involved in mortality. One of these is coagulopathy and disseminated intravascular coagulation caused by SARS-CoV-2. When patients have coagulation disorders, treatment becomes more challenging and mortality rate increases accordingly. The aim of this article is to review the potential mechanisms of coagulopathy in COVID-19 in light of literature data.

Keywords: COVID‑19, coagulopathy, disseminated intravascular coagulation